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On page 1077, Machado et al. 
reveal a new way in which 
aspirin reins in inflammation—
it triggers the destruction 
of proinflammatory signaling 
proteins.
Aspirin’s power was ini-
tially attributed to its inhi-
bition of proinflammatory 
lipids called prostaglandins—
a discovery that won the 
Nobel Prize in 1982. Later, 
aspirin was also shown to 
beef up levels of lipids called 
lipoxins, which help resolve 
inflammation by blocking 
NF-κB activation and the 
recruitment of inflamma-
tory cells.
Lipoxins were recently 
found to activate SOCS2, a 
protein that blocks signals from growth hormone 
receptors by targeting downstream signaling proteins 
to the proteasome. To determine whether SOCS2 
also blocks inflammatory signals, Machado et al. 
fished for its binding partners among molecules that 
transmit innate immune receptor signals.
They now find that SOCS2 binds TRAF2 and 
TRAF6—adaptor proteins that are required for 
cytokine production by activated dendritic cells 
(DCs)—and seems to target them to the proteasome. 
Treating mice with aspirin decreased DC levels of 
cytokines and TRAF2 and TRAF6—effects that 
were mitigated by proteasome inhibitors. The 
same effects were not found in DCs from SOCS2-
deficient mice.
Mice treated with a proteasome inhibitor after 
parasitic infection beat the bug but died from inflam-
matory damage. The deadly inflammation probably 
resulted from prolonged signaling via TRAF2 and 
TRAF6, as inflammation in SOCS2-deficient mice 
was severe even without the inhibitor. Infected mice 
that were left untreated resolved the inflammation 
and survived the infection.
Because proteasome inhibitors also block the 
degradation of IκB—the molecule that holds NF-κB 
in check—they are being developed as alternatives to 
aspirin, which can cause stomach problems and other 
side effects. But the current findings suggest that this 
strategy might be counterproductive. 
Spreading instead of growing
A protein previously hailed as a tumor suppressor has a sinister 
agenda, according to Rolny et al. (page 1155). Although this 
false savior, semaphorin 3B (SEMA3B), tells tumor cells to stop 
growing, it then sends them on their way to grow elsewhere.
Semaphorins were initially identified as extracellular 
navigation signals for growing axons. Some of them are now 
known to enhance tumor progression by increasing the growth 
of blood vessels that feed the tumor. SEMA3B, however, 
is thought to be a tumor suppressor because it also inhibits 
tumor cell proliferation.
Rolny et al. now find that this suppression comes at a 
potentially fatal price. Most tumor suppressors are either absent 
or expressed at low levels in cancerous tissues. But the group 
found high levels of SEMA3B in many cancer cell lines and in 
metastatic tumors from patients. Although SEMA3B inhibited the 
proliferation of these tumor cells in vitro, the poor prognosis of 
these patients suggested that SEMA3B signaling might have 
detrimental effects in vivo.
To test this hypothesis, the authors engineered human 
tumor cells in which SEMA3B expression was controlled by a 
drug-inducible promoter and injected these cells into the skin of 
immune cell-depleted mice. Drug-treated mice had smaller skin 
tumors but developed secondary lung tumors, suggesting that 
SEMA3B induced metastasis.
The authors found that SEMA3B inhibited growth and 
simultaneously triggered metastasis by activating the signaling 
kinase p38. p38 then activated a cell cycle inhibitor and 
induced tumor cells to secrete IL-8, a cytokine known to induce 
leukocyte chemotaxis. The IL-8–secreting tumors were full of 
infiltrating macrophages, which are thought to spur metastasis 
by producing soluble factors such as VEGF. Blocking the release 
of IL-8 in response to SEMA3B, the group found, blocked the 
metastasis of these tumors. 
The destruction (top) of TRAF2 (green) 
via SOCS2 (red) is blocked in mice treated 
with proteasome inhibitors (bottom).
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Infiltration of macrophages (red, left) into tumors is blocked when 
tumors are treated with anti–IL-8 antibody (right).